Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

COPD study investigates why patients struggle to fight lung infections

NCT ID NCT02655302

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a weak immune response to bacteria in COPD patients leads to more lung infections and flare-ups. Researchers collected sputum, blood, and nasal swabs from 23 hospitalized COPD patients during a flare-up and again 8 to 16 weeks later. The goal was to measure specific immune signals (IL-17 and IL-22) to understand why COPD patients are prone to bacterial infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could point toward new ways to prevent or treat bacterial infections in COPD patients.
What could go wrong
This was a small, terminated study with only 23 participants, so results may be limited and not apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

23 people

The number who actually took part.

Started

Jul 2018

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed COPD according GOLD guidelines * Current or ex-smoker (at least 10 pack-years) * Hospitalized for COPD exacerbation Exclusion Criteria: * Asthma or Cystic fibrosis * No other chronic lung disease * Solid Tumor unhealed or not considered in remission * Inhaled drug consumption * Women of childbearing potential without effective contraception * Pregnant or breastfeeding women * Incapable of consent * Lack of social security coverage

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacterial infections Pulmonary disease, chronic obstructive

Contacts and locations

Locations

  • Roubaix hospital

    Roubaix, 59100, France

  • Seclin hospital

    Seclin, 59113, France

  • Tourcoing hospital

    Tourcoing, 59200, France

  • University hospital of Lille

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.